AlphaGrep UK
VKTX icon

AlphaGrep UK’s Viking Therapeutics VKTX Stock Holding History

AlphaGrep UK’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$216K Buy
+6,621
New +$229K 0.06% 653
2026
Q2 		– Sell
-7,004
Closed -$228K – 970
2026
Q1 		$228K Buy
+7,004
New +$225K 0.07% 656

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

AlphaGrep UK's VKTX Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Viking Therapeutics (VKTX) in Q3 2026: 6,621 shares worth $216K. The stake represents 0.06% of the portfolio and ranks #653 among its holdings. This is a return to the name: AlphaGrep UK previously reported a position in VKTX as recently as Q1 2026.

AlphaGrep UK first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $228K in Q1 2026. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • AlphaGrep UK held 6,621 shares of Viking Therapeutics worth $216K as of Q3 2026.
  • Viking Therapeutics was a new AlphaGrep UK position in Q3 2026.
  • Viking Therapeutics made up 0.06% of AlphaGrep UK's portfolio in Q3 2026, its #653 holding.
  • AlphaGrep UK first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • AlphaGrep UK's Viking Therapeutics position peaked at $228K in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.